# Plain Language Summary: Medical Research Tax Credit Bill

This bill creates a new tax break for companies that spend money researching medical countermeasures—basically treatments, vaccines, and other medical solutions for serious health threats like pandemics or bioterrorism. Right now, companies get a tax credit (a reduction in what they owe the government) for general research activities. This bill adds a specific 14 percent tax credit on top of that for companies investing in medical countermeasure research. So if a pharmaceutical company spends $1 million developing a new vaccine or treatment for a dangerous disease, they'd get a $140,000 tax credit to reduce their tax bill.

The bill defines "qualified countermeasures" using an existing legal definition from public health law, which includes things like vaccines, antivirals, and other medical products designed to prevent or treat serious health emergencies. The goal is to encourage companies to invest more in developing these kinds of critical medical solutions by making it financially more attractive through the tax system. Companies can't double-dip though—they can't claim both the regular research credit and this new medical research credit for the same expenses.

For people and patients, this could mean more private investment flowing into research for vaccines and treatments for serious diseases and public health threats. The trade-off is that taxpayers collectively lose some government revenue through these tax credits, which could affect government spending elsewhere. The bill applies to research spending that happens after it's signed into law, so the effects would start showing up in company tax filings going forward.

To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.

Buchanan, Vern

 <p>This bill expands the tax credit for increasing research activities to add a new credit amount equal to 14% of specified medical research expenditures. The bill defines <em>specified medical research expenditures</em> as amounts paid or incurred for research with respect to any qualified countermeasure (i.e., a drug, biological product, or device determined to be a priority in protecting against harm from a biological agent or adverse health condition).</p>